Viatris Inc
VTRS · XNASCIK 1792044fmd_186DVQ34QWS707K1VV91PP5P3YManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 34 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 11,434 | 11,501 | 11,946 | 17,886 | 16,263 | 15,427 | 14,739 | 14,300 |
| Cost of revenue | 7,432 | 7,603 | 8,149 | 12,311 | 9,766 | 8,988 | 9,116 | 9,286 |
| Gross profit | 4,002 | 3,898 | 3,797 | 5,576 | 6,497 | 6,439 | 5,624 | 5,014 |
| Research and development | 705 | 640 | 513 | 681 | 662 | 805 | 809 | 966 |
| Selling, general and administrative | 2,441 | 2,564 | 3,345 | 4,529 | 4,179 | 4,070 | 4,105 | 3,794 |
| Total operating expenses | 3,096 | 3,182 | 4,008 | 5,610 | 4,882 | 5,672 | 5,614 | 7,677 |
| Operating income | 906 | 716 | (211) | (34) | 1,615 | 766 | 10 | (2,663) |
| Interest expense | 542 | 517 | 498 | 636 | 592 | 573 | 550 | 471 |
| Other non-operating income (expense) | (65) | (44) | (13) | 6 | 1,791 | 10 | (83) | (531) |
| Income before taxes | 298 | 154 | (721) | (664) | 2,813 | 203 | (623) | (3,665) |
| Income tax expense | (54) | 138 | (51) | 605 | 735 | 148 | 11 | (150) |
| Net income from continuing operations | 353 | 17 | (670) | (1,269) | 2,079 | 55 | (634) | (3,515) |
| Net income | 353 | 17 | (670) | (1,269) | 2,079 | 55 | (634) | (3,515) |